Coexpression of MAGE-A peptides and HLA class I molecules in hepatocellular carcinoma.
Standard
Coexpression of MAGE-A peptides and HLA class I molecules in hepatocellular carcinoma. / Roch, Nadine; Kutup, Asad; Vashist, Yogesh; Yekebas, Emre F.; Kalinin, Vjacheslav; Izbicki, Jakob R.
in: ANTICANCER RES, Jahrgang 30, Nr. 5, 5, 2010, S. 1617-1623.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Coexpression of MAGE-A peptides and HLA class I molecules in hepatocellular carcinoma.
AU - Roch, Nadine
AU - Kutup, Asad
AU - Vashist, Yogesh
AU - Yekebas, Emre F.
AU - Kalinin, Vjacheslav
AU - Izbicki, Jakob R.
PY - 2010
Y1 - 2010
N2 - Melanoma antigen (MAGE)-A derived peptides are tumour-specific and induce a strong in vitro T-cell response, if presented with human leukocyte antigen (HLA) molecules, which are involved in T-cell-mediated immune surveillance. MAGE-A-derived peptides are recognised by autologous cytotoxic T lymphocytes. The MAGE-A expression profile of hepatocellular carcinomas (HCC) was analysed by PCR assay covering MAGE-A transcripts in 13 patients. MAGE-A peptide expression was determined using a reverse transcription-PCR method. Cryostat sections were stained with monoclonal antibodies directed against HLA class I molecules. Twelve (92.3%) out of thirteen tumours expressed one MAGE-A gene. In at least 90% of the tumours, one MAGE-A peptide was expressed. Determination of the HLA status of the tumours showed a significant loss in approximately 40% of the tumours. The tumour-specific expression of MAGE genes and antigens encoded by a MAGE-family gene may represent useful targets for tumour-specific immunotherapy in HCC patients, in addition to established treatment options.
AB - Melanoma antigen (MAGE)-A derived peptides are tumour-specific and induce a strong in vitro T-cell response, if presented with human leukocyte antigen (HLA) molecules, which are involved in T-cell-mediated immune surveillance. MAGE-A-derived peptides are recognised by autologous cytotoxic T lymphocytes. The MAGE-A expression profile of hepatocellular carcinomas (HCC) was analysed by PCR assay covering MAGE-A transcripts in 13 patients. MAGE-A peptide expression was determined using a reverse transcription-PCR method. Cryostat sections were stained with monoclonal antibodies directed against HLA class I molecules. Twelve (92.3%) out of thirteen tumours expressed one MAGE-A gene. In at least 90% of the tumours, one MAGE-A peptide was expressed. Determination of the HLA status of the tumours showed a significant loss in approximately 40% of the tumours. The tumour-specific expression of MAGE genes and antigens encoded by a MAGE-family gene may represent useful targets for tumour-specific immunotherapy in HCC patients, in addition to established treatment options.
M3 - SCORING: Zeitschriftenaufsatz
VL - 30
SP - 1617
EP - 1623
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 5
M1 - 5
ER -
